血管紧张素受体脑啡肽酶抑制剂在心力衰竭治疗中的回顾与进展研究

Review and Progress of Angiotensin Receptor Neprilysin Inhibitor in Management of Heart Failure

心力衰竭是心脏疾病的终末阶段,其病死率高,预后差,为社会经济带来巨大负担。传统的心力衰竭治疗主要以抑制肾素-血管紧张素-醛固酮系统和交感神经系统为基础,近年来研究发现,联合脑啡肽酶抑制剂和血管紧张素受体阻滞剂可明显改善心力衰竭患者预后,成为心力衰竭治疗发展史中的重要转折点。

Heart failure is the terminal stage of heart disease, with high mortality and poor prognosis. The social and economic burden of heart failure is staggering. Inhibition of renin angiotensin aldosterone and sympathetic nervous systems is the foundation of traditional treatment of heart failure. In recent years, some studies have found that combining an ACE inhibitor and a neprilysin inhibitor can significantly improve morbidity and mortality. This will become a turning point in the history of heart failure treatment.